Abstracts tagged "systemic sclerosis and vasculitis"

Abstract Number: 1856 • 2017 ACR/ARHP Annual Meeting
Patient and Physician Perspectives on Content Value for Educational Material Regarding Rare Rheumatic Diseases
Chris Hatzis¹, Elizabeth Soto-Cardona², Jessica K. Gordon² and Robert F. Spiera², ¹Medicine, Hospital for Special Surgery, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Internet-based information is important for patients and their caregivers. For the past 4 years, our academic medical center’s Center for Scleroderma, Vasculitis & Myositis…
Abstract Number: 2194 • 2014 ACR/ARHP Annual Meeting
Blue Digit Syndrome: The Rheumatologist’s Perspective
Helena Borrell¹, Javier Narváez², Eulalia Armengol¹, Milagros Ricse¹, Gloria Albert¹, Sergi Heredia¹, Andrea Zacarias¹, Carmen Gomez Vaquero¹ and Joan Miquel Nolla¹, ¹Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain
Background/Purpose: Blue or purple digit syndrome (or sign) is a cutaneous manifestation of multiple diseases that produce acute or subacute ischemic compromise in one or…
Abstract Number: 736 • 2013 ACR/ARHP Annual Meeting
Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Associated With Systemic Sclerosis In Japan: A Review Of The Literature
Natsumi Nagao¹, Yuri Sadanaga¹, Satoko Tashiro¹, Rie Suematsu¹, Syuichi Koarada¹, Akihide Ohta² and Yoshifumi Tada¹, ¹Rheumatology, Saga University, Saga, Japan, ²Nursing, Saga University, Saga, Japan
Background/Purpose: Cases of Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) during the course of systemic sclerosis (SSc) have recently been reported. Japanese cases of AAV associated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].